Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Aug 23;14(17):3459.
doi: 10.3390/nu14173459.

Berberine in Non-Alcoholic Fatty Liver Disease-A Review

Anna Koperska  1   2 , Agnieszka Wesołek  1   2 , Małgorzata Moszak  1 , Monika Szulińska  1
Affiliations
Review

Berberine in Non-Alcoholic Fatty Liver Disease-A Review

Anna Koperska et al. Nutrients. .

Abstract

The incidence of Non-Alcoholic Fatty Liver Disease (NAFLD) has been rapidly increasing during the last decade. It is a relevant health problem that affects 25% of the general population. NAFLD involves an extensive array of clinical conditions. So far, no approved pharmacological therapy for NAFLD has been developed. Multiple bioactive compounds have been proposed to treat NAFLD. One of the most promising is Berberine (BBR). Its pleiotropic effect positively impacts various cardiometabolic aspects. In this review, we summarize NAFLD, its metabolic and cardiovascular complications, the hepatoprotective effects of BBR due to its broad spectrum of pharmacological effects, and the potential role of BBR in NAFLD therapy. BBR ameliorates NAFLD by affecting numerous abnormalities. It inhibits lipogenesis and gluconeogenesis, improves insulin resistance and lipid profile, and modulates gut microbiota. The exact mechanism underlying these effects is not yet entirely explained. A growing amount of evidence confirming the positive effects of BBR on multiple metabolic pathways, such as lipids and glucose metabolism, energy homeostasis, or gut microbiota modulation, allows us to speculate about the importance of this natural bioactive substance for NAFLD therapy.

Keywords: NAFLD; berberine; metabolic disorders; obesity.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Actions of BBR.
See this image and copyright information in PMC

References

    1. Shabalala S.C., Dludla P.V., Mabasa L., Kappo A.P., Basson A.K., Pheiffer C., Johnson R. The effect of adiponectin in the pathogenesis of non-alcoholic fatty liver disease (NAFLD) and the potential role of polyphenols in the modulation of adiponectin signaling. Biomed. Pharmacother. 2020;131:110785. doi: 10.1016/j.biopha.2020.110785. - DOI - PubMed
    1. Sesti G., Sciacqua A., Fiorentino T.V., Perticone M., Succurro E., Perticone F. Association between Noninvasive Fibrosis Markers and Cardio-Vascular Organ Damage among Adults with Hepatic Steatosis. PLoS ONE. 2014;9:e104941. doi: 10.1371/journal.pone.0104941. - DOI - PMC - PubMed
    1. Houttu V., Boulund U., Grefhorst A., Soeters M.R., Pinto-Sietsma S.-J., Nieuwdorp M., Holleboom A.G. The role of the gut microbiome and exercise in non-alcoholic fatty liver disease. Ther. Adv. Gastroenterol. 2020;13:1756284820941745. doi: 10.1177/1756284820941745. - DOI - PMC - PubMed
    1. Yki-Järvinen H. Nutritional Modulation of Non-Alcoholic Fatty Liver Disease and Insulin Resistance. Nutrients. 2015;7:9127–9138. doi: 10.3390/nu7115454. - DOI - PMC - PubMed
    1. Luo Y., Tian G., Zhuang Z., Chen J., You N., Zhuo L., Liang B., Song Y., Zang S., Liu J., et al. Berberine prevents non-alcoholic steatohepatitis-derived hepatocellular carcinoma by inhibiting inflammation and angiogenesis in mice. Am. J. Transl. Res. 2019;11:2668–2682. - PMC - PubMed